Association between Polymorphisms of the AKT1 Gene Promoter and Risk of the Alzheimer's Disease in a Chinese Han Population with Type 2 Diabetes

CNS Neuroscience and Therapeutics

Volumn 21, Issue 8, 2015, Pages 619-625

  Liu, Sheng Yuan ^a,b   Zhao, He Dan ^c   Wang, Jin Long ^c   Huang, Tong ^b   Tian, Hua Wei ^d   Yao, Li Fen ^e   Tao, Hua ^a   Chen, Zhong Wei ^b   Wang, Chang Yi ^b   Sheng, Si Tong ^f   Li, Hua ^g   Zhao, Bin ^a   Li, Ke Shen ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b Shenzhen Nanshan Center for Chronic Disease Control   (China)

^c The Kangci Hospital   (China)

^d Futian Hospital   (China)

^e THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^f SHENZHEN UNIVERSITY   (China)

^g Software Park   (China)

Author keywords

Alzheimer's disease; Insulin signaling pathway; Polymorphism; Type 2 diabetes; V akt murine thymoma viral oncogene homolog 1

Indexed keywords

PROTEIN AKT1; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; PROTEIN KINASE B;

AGED; AKT1 GENE; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CHINESE; COGNITION; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION; GENETICS; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; RISK;

EID: 84937411299     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12430     Document Type: Article

References (33)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342.
2. Alzheimer's disease International. World Alzheimer Report 2009-2011. 2012. http://www.alz.co.uk/research/world-report.
3. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.
4. Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimer's disease: The enemy within. J Alzheimers Dis 2008;13:393-405.
5. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-388.
6. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 2002;25:22-26.
7. Meetoo D, McGovern P, Safadi R. An epidemiological overview of diabetes across the world. Br J Nurs 2007;16:1002-1007.
8. Herholz K, Schopphoff H, Schmidt M, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 2002;43:21-26.
9. Craft S, Asthana S, Cook DG, et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: Interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003;28:809-822.
10. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 2011;225:54-62.
11. Karege F, Meary A, Perroud N, et al. Genetic overlap between schizophrenia and bipolar disorder: A study with AKT1 gene variants and clinical phenotypes. Schizophr Res 2012;135:8-14.
12. Devaney JM, Gordish-Dressman H, Harmon BT, et al. AKT1 polymorphisms are associated with risk for metabolic syndrome. Hum Genet 2011;129:129-139.
13. Kim MJ, Kang HG, Lee SY, et al. AKT1 polymorphisms and survival of early stage non-small cell lung cancer. J Surg Oncol 2012;105:167-174.
14. Wang X, Cao Z, Jiang J, et al. AKT1 polymorphisms are associated with tuberculosis in the Chinese population. Int J Immunogenet 2010;37:97-101.
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
16. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S5-S20.
17. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-746.
18. Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin Chem Lab Med 2011;49:375-383.
19. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol 1997;145:301-308.
20. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997;272:19547-19553.
21. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis J Neural Transm 1998;105:415-422.
22. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997;275:661-665.
23. Ksiezak-Reding H, Pyo HK, Feinstein B, Pasinetti GM. Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. Biochim Biophys Acta 2003;1639:159-168.
24. Karege F, Perroud N, Schurhoff F, et al. Association of AKT1 gene variants and protein expression in both schizophrenia and bipolar disorder. Genes Brain Behav 2010;9:503-511.
25. Xiromerisiou G, Hadjigeorgiou GM, Papadimitriou A, Katsarogiannis E, Gourbali V, Singleton AB. Association between AKT1 gene and Parkinson's disease: A protective haplotype. Neurosci Lett 2008;436:232-234.
26. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999;16:93-112.
27. Cook T, Gebelein B, Urrutia R. Sp1 and its likes: Biochemical and functional predictions for a growing family of zinc finger transcription factors. Ann N Y Acad Sci 1999;880:94-102.
28. Philipsen S, Suske G. A tale of three fingers: The family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res 1999;27:2991-3000.
29. Chu S, Ferro TJ. Sp1: Regulation of gene expression by phosphorylation. Gene 2005;348:1-11.
30. Jackson SP, MacDonald JJ, Lees-Miller S, Tjian R. GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell 1990;63:155-165.
31. Docagne F, Gabriel C, Lebeurrier N, et al. Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription. Biochem J 2004;383:393-399.
32. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol 2004;24:865-874.
33. Heicklen-Klein A, Ginzburg I. Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J Neurochem 2000;75:1408-1418.